Free to use. No sign-up needed.

How can I help you sell?

Watch the 2-min demo Like ChatGPT married your dream sales app

Simple chat.
Deep intelligence.

Ask Tnuki anything. Behind the chat, purpose-built agents dig through 50+ proprietary data sources, the open web, and fresh buying signals. In minutes, Tnuki hands you an action-oriented table: prioritized accounts, verified decision makers, events to attend. The depth of an institutional-grade research team, at the speed of a chat.

Start for free No signup, no credit card.
Tnuki mascot Clover
Decorative rocks

Every data source you need, in one chat

Tnuki integrates proprietary B2B datasets, 40+ scientific & regulatory sources, and searches the live web, news, and filings.

1B+ Professional profiles Automatically verified email and phone
60M+ Companies Firmographics, funding, hiring
Live web and Press Releases GlobeNewswire, institutional directories, social
ClinicalTrials.gov Global clinical trial registry PubMed 37M+ biomedical citations NIH RePORTER NIH-funded research & grants openFDA FDA drug & safety data Drugs@FDA Every FDA-approved drug See all sources →
Decorative vine

Deep account research,
run in minutes

1

Chat in plain English

Start with a single sentence. Tnuki asks a couple of quick questions to zero in on your ideal customer — no filters, no database setup.

2

Sourced, enriched, and verified

Tnuki queries proprietary, vertical-specific databases and the live web, then synthesizes a researched account and contact picture — and verifies every email and phone, automatically.

3

Every morning: the accounts heating up

Tnuki reads 1,000+ signal sources while you sleep, then surfaces the accounts moving in your market — the trigger, the context, and the decision-maker to reach. Your research engine never stops running.

tnuki.com
Proteomics for AI drug discovery
I sell high-plex proteomics and am looking for AI drug discovery companies
Researching high-plex proteomics... Gathering targeting details...
Which buyers should I target first?
Head of Platform Head of Discovery Head of CompBio Head of AI
Or type your own response...
I sell high-plex proteomics and am looking for AI drug discovery companies
Q: Which buyers should I target?
Head of AI, Head of CompBio
Q: What company segment?
Series B/C biotech
B2B database Web search Enriched 18
Found 18 AI & CompBio leads across Series B/C biotech.
Message Tnuki... Send
#CompanyPersonEmail Draft
Your enriched list will appear here
#CompanyPersonEmail Draft
1
Insitro
Insitroin
South San Francisco, CA
201-500↗ Growing
Machine-learning-driven drug discovery
Laura Whitfield
Laura Whitfieldin
South San Francisco, CA
l.whitfield@insitro.com
Head of AI
  • Builds ML models for target discovery
  • Curates multi-omics training data
  • Drives data-acquisition strategy
High-plex proteomics for your ML models
Hi Laura — Insitro's models are only as good as their training data. High-plex proteomics adds a functional protein layer to your multi-omics sets, surfacing targets genomics alone can miss...
2
Valo Health
Valo Healthin
Boston, MA
201-500↗ Growing
End-to-end AI drug discovery platform
James Nakamura
James Nakamurain
Boston, MA
j.nakamura@valohealth.com
Head of CompBio
  • Leads computational target ID
  • Integrates omics into models
  • Owns the data platform
Protein-level features for target ID
Hi James — As Valo scales computational discovery, high-plex proteomics gives your pipelines thousands of protein readouts per sample — richer signal than transcriptomics for predicting response...
3
VantAI
VantAIin
New York, NY
60-80↗ Growing
Generative AI for protein design
Priya Malhotra
Priya Malhotrain
New York, NY
p.malhotra@vant.ai
(212) 555-0193
Head of ML Platform
  • Runs the ML data platform
  • Sources high-dimensional data
  • Feeds protein-interaction models
Proteomic data for your platform
Hi Priya — VantAI's protein-design models thrive on dense protein data. High-plex proteomics profiles thousands of proteins per run, adding the functional signal structure-only models lack...
4
Insitro
Insitroin
South San Francisco, CA
201-500↗ Growing
Machine-learning-driven drug discovery
Sofia Reyes
Sofia Reyesin
South San Francisco, CA
s.reyes@insitro.com
VP, Machine Learning
  • Trains disease-prediction models
  • Evaluates new data modalities
  • Partners on data acquisition
A new data modality for Insitro
Hi Sofia — Curious whether proteomics is on your modality roadmap. High-plex panels produce model-ready protein matrices that complement your imaging and genomics for disease-state prediction...
5
Valo Health
Valo Healthin
Boston, MA
201-500↗ Growing
End-to-end AI drug discovery platform
Rachel Kim
Rachel Kimin
Boston, MA
r.kim@valohealth.com
(617) 555-0247
Head of Data Science
  • Builds target-discovery pipelines
  • Curates proteomic & genomic data
  • Validates model predictions
Validating predictions with proteomics
Hi Rachel — When a model nominates a target, high-plex proteomics confirms protein-level changes fast — closing the loop between prediction and validation across Valo's programs...
6
VantAI
VantAIin
New York, NY
60-80↗ Growing
Generative AI for protein design
Alex Torres
Alex Torresin
New York, NY
a.torres@vant.ai
Director, AI Discovery
  • Develops protein-interaction models
  • Needs deep proteomic features
  • Scales training datasets
Deeper proteomic features for discovery
Hi Alex — Generative protein models need rich training signal. High-plex proteomics delivers high-dimensional, quantitative protein data at scale — the features that sharpen molecular-glue discovery...
6:00 AM

Today's Plays

Spatial Biology · US West Pharma & Biotech

726 stories analyzed overnight

FRI, APR 10

5 plays

+ 11 to know about

Reach out now
Review & send →
Jeff Tanaka To: Jeff Tanaka, Dir. Translational Science, Sidewinder
“I work with several ADC-stage biotechs and one thing that keeps coming up is how critical it is to show clean co-expression data on the target…”
What triggered this
Sidewinder Therapeutics raises $137M Series B to push bispecific ADC pipeline toward IND
Apr 10 — Oversubscribed (Frazier + Novartis) backs a 3-program bispecific ADC pipeline led by SWT012. SEC filing · BioPharma Dive
Reach out now
Review & send →
Priya Varma To: Priya Varma, Dir. Applications Development, Genentech
“Saw the label expansion news — curious how the team is thinking about scaling spatial IHC for companion Dx workflows as demand picks up…”
What triggered this
Genentech secures FDA label expansion for flagship oncology drug
Apr 9 — Expanded indication will pressure companion-Dx volume; three senior Dx hires posted this month confirm staff-up. FDA label update · LinkedIn hires
Good to know
Gilead to acquire ADC specialist Tubulis for up to $5B
Apr 8 — Validates ADC investment; combined oncology portfolio opens cross-sell window in 60-90 days. Gilead press · Endpoints News
C4 Therapeutics × Roche expand DAC collaboration with $20M upfront
Apr 7 — TPD meets ADCs: Roche's DAC expansion is a near-term driver of target-expression and tissue selectivity studies. C4 press · BioSpace
Decorative pot with clovers

Try it live

Explore an actual Tnuki table.

Ask your own follow-ups and explore how Tnuki works.

Live Tnuki table with verified prospects, buying signals, and personalized email drafts
Try it live Click anywhere to open this thread in a new tab.

Pricing & comparison

Try Tnuki for free

Start instantly for free. No sign-up, no credit card.

Tnuki Apollo Clay
Data freshness Real-time, live web Cached DB On-demand via providers
Coverage 1B+ people, 100M+ companies ~250M people Requires other providers
Setup time Minutes Weeks Weeks
Usable free tier Access for free
Fully conversational (chat-first)
AI email drafts Manual setup
Trigger-grounded personalization Manual setup

Competitor pricing and estimates reflect public pricing pages and vendor-disclosed figures.

FAQ

Frequently asked questions

Common questions about Tnuki and deep account research. (Last updated June 2026)

What is Tnuki?
Tnuki is the deep-research engine for sales and market intelligence — the depth of an institutional-grade research team, at the speed of a chat. Purpose-built agents dig through 50+ proprietary data sources, the open web, and fresh buying signals (funding rounds, exec hires, regulatory filings, LinkedIn posts), then hand your team a built target list, the accounts heating up, and the decision-makers to meet — plus account dossiers and outbound emails drafted in your voice. It’s built for research-heavy verticals like life sciences, scientific instruments, and aerospace and defense. Tnuki is augmented, not autonomous: a human reviews and sends every email. Free to start, no signup, no credit card.
How is Tnuki different from using ChatGPT for sales research?
General assistants like ChatGPT are great at language, but for sales research they’re limited to the open web and their training data — no proprietary databases, no real-time buying signals, no verified contacts, and no memory of your accounts. Tnuki is a purpose-built research engine: its agents dig through 50+ proprietary data sources alongside the public web, monitor 1,000+ sources for buying triggers, verify decision-makers, and compile account dossiers and drafted outreach — all grounded in sources you can click to verify. You get the ease of a chat with depth a general model structurally can’t reach.
How is Tnuki different from Apollo, Clay, ZoomInfo, or AI SDRs?
Two camps, one gap. Apollo, ZoomInfo, and Clay are database-first: you build filters and workflows on top of a single generic dataset. AI SDRs like 11x.ai ($5,000+/month) and Artisan are autonomous black boxes that optimize for volume on that same generic data. Tnuki is research-first and augmented: purpose-built agents — tuned per vertical — dig through 50+ proprietary, vertical-specific data sources and the public web for depth that horizontal tools miss, while your team sees every search, enrichment, and draft and reviews and sends every email. You get an institutional-grade research team’s depth and AI speed without giving up control.
Which industries and verticals does Tnuki support?
Tnuki is built for research-heavy verticals — markets where selling takes real research and horizontal databases fall short. Coverage is deepest in life sciences and biotech, scientific instruments, and aerospace and defense, with strong support across healthcare, diagnostics, and other technical or regulated industries. For each vertical, the agents are tuned to the proprietary databases, registries, and buying signals that matter there — clinical and regulatory milestones in life sciences, grant and contract awards in instruments and defense — so the research reflects how that market actually buys. Tnuki still works for general B2B sales; its edge is depth in specialized markets.
What data sources does Tnuki use?
Tnuki goes well beyond a single database. Its agents pull from 50+ proprietary data sources — vertical-specific databases, registries, and specialist directories that horizontal tools like ZoomInfo or Apollo don't carry — alongside the public web, professional networks, contact-data providers (10+ via waterfall enrichment), news, job boards, funding databases, and 1,000+ live buying-signal sources. Everything is queried in real time, so the data is fresher and deeper than a static database, and every result links back to its source so your team can verify it. The exact source mix is tuned per vertical.
Can Tnuki do market intelligence, not just prospecting?
Yes. Prospect lists are one output, but Tnuki is a deep-research engine for market intelligence too. The same purpose-built agents can compile account dossiers, build market maps of a vertical, lay out competitive landscapes, and map the decision-makers and buying committees inside target accounts — in addition to producing a built target list, the accounts heating up, and ready-to-send outreach. It’s the depth of a research team, at the speed of a chat, whether you're building pipeline or sizing a market.
What are Today's Plays?
Today's Plays are recurring, AI-generated email digests that monitor your market and target accounts. Tnuki's agents scan news, LinkedIn posts, X/Twitter activity, job postings, SEC filings, funding databases, and proprietary, vertical-specific sources, then send you a concise summary with personalized outreach ready to send. Think of it as a research team that never sleeps, delivering actionable intelligence straight to your inbox — daily, weekly, or on your preferred cadence.
Is Tnuki free to use?
Yes. Tnuki has a free tier — you can use the Tnuki chat to research accounts, build a target list, verify decision-makers, and draft outreach, plus receive daily plays at a regular cadence. No signup, no credit card required. Paid plans (with higher-volume usage and more frequent plays) will be announced separately.

See what Tnuki can do

Explore our deep integration of account and market intelligence, in one easy-to-use chat.

Or talk to a human →